Latest News

The pharmaceutical company has only two approved therapies, but others should be on the way soon.

Netflix's high-margin business model and slowing growth rate set the stage for the introduction of a dividend program.

Hotel franchisor Choice Hotels (NYSE:CHH) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 2.5% year on year to $458.3 million. Its no...

Beauty sales surged 8% but margins stumbled in North America, exposing an execution gap management must close.

This popular tech ETF would have doubled your money (and more) in the past five years.

Three critical earnings reports will dictate the market's direction in the first week of November.

Palantir's next earnings report could answer crucial questions about its growth and valuation. Discover the financial measures that may determine whether its impressive momentum can continue.

When safe investments yield more, riskier investments aren't as attractive.

Is history sounding the death knell for this bull market?

Offshore energy producer Talos Energy (NYSE:TALO) will be announcing earnings results tomorrow after market hours. Here’s what to expect. Talos Energy beat a...

Offshore energy producer Talos Energy (NYSE:TALO) will be reporting earnings tomorrow after market close. Here’s what investors should know. Talos Energy bea...

Oil and gas producer SM Energy (NYSE:SM) will be announcing earnings results tomorrow after the bell. Here’s what to expect. SM Energy beat analysts’ revenue...

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys...

Beauty products company Estée Lauder (NYSE:EL) reported calendar Q3 2026 (fiscal Q1 2027) results topping the market’s revenue expectations, with revenue up ...

Lower funding costs and disciplined credit selection are fueling asset growth toward a $5 billion target.

Alphabet is taking a tumble, and now is the perfect time to take action.

Read inspirational quotes about flourishing amid change, being willing to evolve and helping others.

Robinhood and Nu are reshaping financial services in different markets, but their contrasting valuations could make one a more attractive investment.

Palantir earnings are due late Monday with sales growth seen slowing, finally.

Cost discipline is turning cyclical weakness into structural advantage, positioning the business to capture upside when demand recovers.

AbbVie replaced one megablockbuster already. It may have found its next one.

SpaceX gets the headlines, but Rocket Lab and Redwire offer other ways to invest in the space boom, with very different valuations and risks.

Tech stocks are officially on the menu under Berkshire Hathaway’s new boss.